Psyence Group Inc. announced that it has exported purified pharmaceutical grade psilocybin mushroom extract to its Contract Development & Manufacturing Organisation ("CDMO") partner in the United Kingdom. The product was exported from Psyence's federally licensed ISO22000 certified production facility in Southern Africa. Psyence has partnered with a highly experienced Current Good Manufacturing Practice (CGMP) compliant full-lifecycle pharmaceutical services company, which is a trusted partner to the world's most innovative biotech companies and leading pharmaceutical companies.

The CDMO partnership is in line with Psyence Group's pharmaceutical product development and intellectual property strategy. Psyence's pharmaceutical psilocybin extract will be used by the CDMO to develop standardised pharmaceutical grade psilocybin and psilocin extracts, which will be formulated into a final product for regulatory approval internationally. Psyence is developing global partnerships for the supply of its pharmaceutical grade psilocybin products for research, clinical trials, and drug development.